Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations

被引:9
作者
Sevco, Tyler J. [1 ]
Masch, William R. [1 ]
Maturen, Katherine E. [1 ]
Mendiratta-Lala, Mishal [1 ]
Wasnik, Ashish P. [1 ]
Millet, John D. [1 ]
机构
[1] Univ Michigan, Michigan Med, Dept Radiol, Div Abdominal Radiol, UH BID520D,SPC5030,1500 E Med Ctr, Ann Arbor, MI 48109 USA
关键词
hepatocellular carcinoma; LI-RADS; ultrasound; HEPATOCELLULAR-CARCINOMA; SURVEILLANCE; GUIDELINES; MANAGEMENT;
D O I
10.2214/AJR.20.23447
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of the study is to evaluate the outcomes of ultrasound (US) LI-RADS category US-3 observations detected at US performed for hepatocellular carcinoma (HCC) screening and surveillance on the basis of subsequently performed multiphase MRI or CT or histopathology. MATERIALS AND METHODS. In this retrospective analysis, 267 patients at high risk for HCC (161 men and 106 women; mean [+/- SD] age, 58.6 +/- 12.2 years) underwent screening liver US between January 2017 and June 2019 and were assigned US-3 observations on a prospective clinical basis using the US LI-RADS algorithm. The results of follow-up imaging studies and/or histopathology were analyzed. RESULTS. Visualization scores assigned at US were A (40.8% [109/267]), B (52.8% [141/267]), and C (6.4% [17/267]). Reasons for US-3 observations included a measurable mass of 1 cm or larger (88.8% [237/267]; mean size, 1.8 +/- 1.0 cm; range, 1.0-6.9 cm), an area of parenchymal distortion of 1 cm or greater (7.9% [21/267]; mean size, 1.8 +/- 0.9 cm; range, 1.0-4.0 cm), or a new venous thrombus (3.4% [9/267]). Confirmatory testing with multiphase contrast-enhanced MRI or CT or with histopathology was available for 81.6% (218/267) of patients. Causes of US-3 observations included no abnormality at MRI or CT (41.3% [90/218]), a benign lesion (32.6% [71/218]), a LI-RADS category 3 (LR-3) observation at MRI or CT (5.5% [12/218]), a LI-RADS category 4 or 5 (LR-4 or LR-5) observation at MRI or CT or identification of HCC at histopathology (18.8% [41/218]),and an LR-M (denoting probably or definitely malignant but without specific features for HCC) observation at MRI or CT or other malignancy at histopathology (1.8% [4/218]). The PPV of a US-3 observation for probable or definite HCC was 18.8%, and for any malignancy it was 20.6%. CONCLUSION. In the HCC screening population, approximately one in five US-3 observations represents probable or definite HCC at multiphase MRI or CT or HCC at histopathology. These findings support current US LI-RADS guidelines to pursue further evaluation with multiphase cross-sectional imaging for US-3 observations.
引用
收藏
页码:644 / 650
页数:7
相关论文
共 50 条
  • [21] Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS
    Ding, Jianmin
    Long, Lei
    Zhang, Xiang
    Chen, Chen
    Zhou, Hongyu
    Zhou, Yan
    Wang, Yandong
    Jing, Xiang
    Ye, Zhaoxiang
    Wang, Fengmei
    EUROPEAN RADIOLOGY, 2021, 31 (02) : 847 - 854
  • [22] LI-RADS category 3, 4, and M observations: a multiple parameters diagnostic model for hepatocellular carcinoma
    Chen, Jianwei
    Chen, Huizhen
    Zheng, Dechun
    Yan, Chuan
    Ye, Rongping
    Wen, Liting
    Li, Yueming
    ACTA RADIOLOGICA, 2023, 64 (12) : 2977 - 2986
  • [23] Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS
    Choi, Hailey H.
    Perez, Marcelina G.
    Millet, John D.
    Liang, Tie
    Wasnik, Ashish P.
    Maturen, Katherine E.
    Kamaya, Aya
    ABDOMINAL RADIOLOGY, 2019, 44 (04) : 1415 - 1422
  • [24] What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
    Maryam Ghadimi
    Jason Birnbaum
    Ihab R. Kamel
    Claude B. Sirlin
    Victoria Chernyak
    European Radiology, 2022, 32 : 3327 - 3333
  • [25] What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
    Ghadimi, Maryam
    Birnbaum, Jason
    Kamel, Ihab R.
    Sirlin, Claude B.
    Chernyak, Victoria
    EUROPEAN RADIOLOGY, 2022, 32 (05) : 3327 - 3333
  • [26] State of the Art: LI-RADS for Contrast-enhanced US
    Quaia, Emilio
    RADIOLOGY, 2019, 293 (01) : 4 - 14
  • [27] Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M
    Heo, Subin
    Kang, Hyo Jeong
    Choi, Sang Hyun
    Kim, Sehee
    Yoo, Youngeun
    Choi, Won-Mook
    Kim, So Yeon
    Lee, Seung Soo
    EUROPEAN RADIOLOGY, 2024, 34 (05) : 2974 - 2985
  • [28] Clinicoradiographic predictors of progression of an intermediate hepatic lesion (LI-RADS 3) to hepatocellular carcinoma (LI-RADS 5)
    Hannan, Lindsay M.
    Ojeda, Patricia I.
    Mieloszyk, Rebecca J.
    Harris, William P.
    Park, James O.
    Bhargava, Puneet
    HEPATOMA RESEARCH, 2021, 7 : 7 - 78
  • [29] Limitations Associated With Assessing Liver Ultrasound Quality Using US LI-RADS Visualization Score When Utilizing Acquired Images Reply
    Singal, Amit G.
    Schoenberger, Haley
    Fetzer, David
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1618 - 1619
  • [30] Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018
    Goins, Stacy M.
    Adamo, Robert G.
    Lam, Eric
    Costa, Andreu F.
    van der Pol, Christian B.
    Salameh, Jean-Paul
    Dawit, Haben
    McInnes, Matthew D. F.
    Bashir, Mustafa R.
    RADIOLOGY, 2023, 307 (04)